Match!
Jan N. Basile
Medical University of South Carolina
CardiologyIntensive care medicineDiabetes mellitusMedicineBlood pressure
208Publications
30H-index
5,552Citations
What is this?
Publications 215
Newest
Source
Abstract Background In 1974, the American Dental Association first considered recommending that dental offices measure blood pressure (BP) routinely, and it has been further encouraged since 2006. Investigators in several dental publications have recommended cancellation of dental procedures based solely on BP greater than 180/110 millimeters of mercury for urgent oral health care and greater than 160/100 mm Hg for elective oral health care, in the absence of prior medical consultation. Methods ...
Source
#2Adriana M. HungH-Index: 21
Last. William C. CushmanH-Index: 59
view all 14 authors...
The SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated reduced cardiovascular outcomes. We evaluated diabetes mellitus incidence in this randomized trial that compared intensive blood...
#1Christianne L. Roumie (VUMC: Vanderbilt University Medical Center)H-Index: 27
#2Adriana M. Hung (VUMC: Vanderbilt University Medical Center)H-Index: 21
Last. William C. Cushman (UTHSC: University of Tennessee Health Science Center)H-Index: 59
view all 14 authors...
1 CitationsSource
#1Hertzel C. Gerstein (HHS: Hamilton Health Sciences)H-Index: 93
#2Robert G. Hart (Population Health Research Institute)H-Index: 83
Last. T. Temelkova-KurktschievH-Index: 20
view all 29 authors...
Summary Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c w...
1 CitationsSource
#1Hertzel C. Gerstein (Population Health Research Institute)H-Index: 93
#2Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
Last. William ZigrangH-Index: 2
view all 1456 authors...
Summary Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-term effect of the GLP-1 receptor agonist dulaglutide on renal outcomes in an exploratory analysis of the REWIND trial of the effect of dulaglutide on cardiovascular disease. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries. Men and women aged at leas...
18 CitationsSource
#1Hertzel C. Gerstein (Population Health Research Institute)H-Index: 93
#2Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
Last. William ZigrangH-Index: 2
view all 1456 authors...
Summary Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A 1c (HbA 1c ) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of...
52 CitationsSource
#1Michel Azizi (Paris V: Paris Descartes University)H-Index: 41
#2Roland E. SchmiederH-Index: 87
Last. Ajay J. Kirtane (CUMC: Columbia University Medical Center)H-Index: 59
view all 20 authors...
Background: The multicenter, international, randomized, blinded, sham-controlled RADIANCE-HTN SOLO trial (A Study of the ReCor Medical Paradise System in Clinical Hypertension) demonstrated a 6.3 m...
3 CitationsSource
Source
#1Ajay J. Kirtane (NewYork–Presbyterian Hospital)H-Index: 11
#2Roland E. SchmiederH-Index: 87
Last. Michel Azizi (Paris V: Paris Descartes University)H-Index: 14
view all 14 authors...
The RADIANCE-HTN SOLO trial is the first randomized, blinded, sham-controlled study of endovascular ultrasound renal denervation (RDN) to treat hypertension in an off-medication population. Anatomic and procedural predictors of response to this therapy have not been described. Between March 2016
2 CitationsSource
12345678910